Author

A. Kayabolen

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Bioengineering· 1 Biophysics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 4 Organism:human· 3 Approach:experimental assay· 2 Assay:ChIP-seq· 1 Approach:deep learning· 1 Approach:genetic perturbation / CRISPR· 1 Research Focus:host-pathogen & immune response· 1 Assay:proteomics· 1

Frequent Co-Authors

T. Bagci-Onder· 4 shared A. Akdemir· 1 shared A. C. Aksu· 1 shared A. Cingoz· 1 shared A. D. Cavga· 1 shared A. Durgun· 1 shared A. Idris· 1 shared A. Odabas· 1 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 16 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

T. Bagci-Onder

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

ACE2-Coated Virus-Like Particles Effectively Block SARS-CoV-2 Infection

C. Bayraktar, A. Kayabolen, A. Odabas, A. Durgun, I. Kok, K. Sevinc, A. Supramaniam, A. Idris, T. Bagci-Onder

This paper develops ACE2-coated virus-like particles (ACE2-VLPs) that effectively neutralize SARS-CoV-2, including variants, and show superior efficacy compared to ACE2-expressing extracellular vesicles.

bioRxiv · Sep 19, 2023 · PreprintBioengineering

EPIKOL, a chromatin-focused CRISPR/Cas9-based screening platform, to identify cancer-specific epigenetic vulnerabilities

O. Yedier-Bayram, B. Gokbayrak, A. C. Aksu, A. D. Cavga, A. Kayabolen, E. Y. Kala, G. Karabiyik, R. Gunsay, T. Morova, F. Uyulur, N. A. Lack, T. T. Onder, T. Bagci-Onder

The paper introduces EPIKOL, a CRISPR-Cas9 library targeting epigenetic modifiers, and demonstrates its utility in identifying cancer-specific epigenetic vulnerabilities in breast and prostate cancer.

bioRxiv · May 14, 2021Cancer Biology

The neutralization effect of Montelukast on SARS-CoV-2 is shown by multiscale in silico simulations and combined in vitro studies

S. Durdagi, T. Avsar, M. D. Orhan, M. Serhatli, B. K. Balcioglu, H. U. Ozturk, A. Kayabolen, Y. Cetin, S. Aydinlik, T. Bagci-Onder, S. Tekin, H. Demirci, M. Guzel, A. Akdemir, S. Calis, , Y. Yumak

This paper shows Montelukast inhibits SARS-CoV-2 by targeting both Spike/ACE2 and main protease through in silico and in vitro studies.

bioRxiv · Dec 26, 2020Biophysics

Orthogonal targeting of KDM6A/B and HDACs mediates potent therapeutic effects in IDH1-mutant glioma

A. Kayabolen, E. Yilmaz, G. N. Sahin, F. Seker-Polat, A. Cingoz, B. Isik, S. Acar, S. Karahuseyinoglu, H. Wakimoto, D. P. Cahill, I. Solaroglu, A. P. Cribbs, U. Oppermann, T. Bagci-Onder

This study identifies GSK-J4 and Belinostat as effective therapies for IDH1-mutant glioma by targeting KDM6A/B and HDACs, showing synergistic effects in vitro and in vivo.

bioRxiv · Nov 26, 2020 · PreprintCancer Biology